Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue.

BACKGROUND Apolipoprotein A-IV (ApoA-IV) is a 46 kD glycoprotein thought to protect against atherosclerosis. It is synthesized primarily in epithelial cells of the small intestine. Elevated plasma concentrations of ApoA-IV in patients with chronic kidney disease suggest that the human kidney is involved in ApoA-IV metabolism. METHODS To investigate whether the human kidney directly metabolizes ApoA-IV and which kidney tissue compartment is involved therein, ApoA-IV was localized by immunohistochemistry in 28 healthy kidney tissue samples obtained from patients undergoing nephrectomy. ApoA-IV mRNA expression was analyzed by real-time polymerase chain reaction (PCR) to exclude de novo synthesis in the kidney. RESULTS ApoA-IV immunostaining was detected in proximal and distal tubular cells, capillaries and blood vessels but not inside glomeruli. ApoA-IV was predominantly found in the brush border of proximal tubules and in intracellular granules and various plasma membrane domains of both proximal and distal tubules. mRNA expression analysis revealed that no ApoA-IV was produced in the kidney. CONCLUSION The immunoreactivity of ApoA-IV observed in kidney tubular cells suggests a direct role of the human kidney in ApoA-IV metabolism. The granular staining pattern probably represents lysosomes degrading ApoA-IV. The additional ApoA-IV localization in distal tubules suggests a rescue function to reabsorb otherwise escaping ApoA-IV in case proximal tubules cannot reabsorb all ApoA-IV. Since no mRNA expression could be detected in any kidney cells, the observed ApoA-IV immunoreactivity represents uptake and not de novo synthesis of ApoA-IV.

[1]  D. Cavallone,et al.  Tamm-Horsfall glycoprotein: biology and clinical relevance. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  F. Kronenberg,et al.  Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls Published, JLR Papers in Press, June 1, 2003. DOI 10.1194/jlr.M300060-JLR200 , 2003, Journal of Lipid Research.

[3]  F. Kronenberg,et al.  Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. , 2003, Kidney international. Supplement.

[4]  Gerd Schmitz,et al.  Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. , 2003, Clinical chemistry.

[5]  F. Kronenberg,et al.  Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. , 2002, Journal of the American Society of Nephrology : JASN.

[6]  A. Lichtenstein,et al.  Human apolipoprotein A-IV metabolism within triglyceride-rich lipoproteins and plasma. , 2001, Atherosclerosis.

[7]  Y. Zhao,et al.  The relationship between plasma apolipoprotein A-IV levels and coronary heart disease. , 2001, Chinese medical journal.

[8]  F. Kronenberg,et al.  Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. , 2000, Journal of the American College of Cardiology.

[9]  F. Kronenberg,et al.  Preparative free-solution isotachophoresis for separation of human plasma lipoproteins: apolipoprotein and lipid composition of HDL subfractions. , 2000, Journal of lipid research.

[10]  D. Sparks,et al.  Role of the kidney in regulating the metabolism of HDL in rabbits: evidence that iodination alters the catabolism of apolipoprotein A-I by the kidney. , 2000, Biochemistry.

[11]  T. Willnow,et al.  Essential role of megalin in renal proximal tubule for vitamin homeostasis. , 1999, Journal of the American Society of Nephrology : JASN.

[12]  H. Brewer,et al.  Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipoprotein holoparticle endocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Chapelle,et al.  The intrinsic factor–vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein , 1999, Nature Medicine.

[14]  M. Vohl,et al.  Apolipoprotein A-I charge and conformation regulate the clearance of reconstituted high density lipoprotein in vivo. , 1999, Journal of lipid research.

[15]  J. Qiao,et al.  Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. , 1997, The Journal of clinical investigation.

[16]  P. Tso,et al.  Rapid synthesis and secretion of intestinal apolipoprotein A-IV after gastric fat loading in rats. , 1997, The American journal of physiology.

[17]  P. Denéfle,et al.  Protection Against Atherogenesis in Mice Mediated by Human Apolipoprotein A-IV , 1996, Science.

[18]  S. Yokoyama,et al.  Activation of human plasma cholesteryl ester transfer protein by human apolipoprotein A-IV. , 1996, Biochimica et biophysica acta.

[19]  A. von Eckardstein,et al.  Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[20]  F. Kronenberg,et al.  Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. , 1995, Journal of the American Society of Nephrology : JASN.

[21]  R. Brasseur,et al.  Identification of specific amphipathic alpha-helical sequence of human apolipoprotein A-IV involved in lecithin:cholesterol acyltransferase activation. , 1994, The Journal of biological chemistry.

[22]  F. Kronenberg,et al.  Effect of sample storage on the measurement of lipoprotein[a], apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. , 1994, Journal of lipid research.

[23]  P. Gambert,et al.  Comparative effects of purified apolipoproteins A-I, A-II, and A-IV on cholesteryl ester transfer protein activity. , 1994, Journal of lipid research.

[24]  J. Fruchart,et al.  Characterization of apoA-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[25]  G. Utermann,et al.  Plasma apolipoprotein A‐IV metabolism in patients with chronic renal disease , 1992, European journal of clinical investigation.

[26]  J. Fruchart,et al.  Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. , 1990, The Journal of biological chemistry.

[27]  I. Goldberg,et al.  Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. , 1990, The Journal of biological chemistry.

[28]  C. Hornick,et al.  Metabolism of apoE-free high density lipoproteins in rat hepatoma cells: evidence for a retroendocytic pathway. , 1990, Journal of lipid research.

[29]  P. Gambert,et al.  Evidence for high density lipoproteins as the major apolipoprotein A-IV-containing fraction in normal human serum. , 1989, Journal of lipid research.

[30]  V. Clavey,et al.  Purification of human apolipoprotein A-IV by fast protein liquid chromatography. , 1989, Journal of chromatography.

[31]  M. Seishima,et al.  An increased apo A-IV serum concentration of patients with chronic renal failure on hemodialysis. , 1987, Clinica chimica acta; international journal of clinical chemistry.

[32]  M. Boguski,et al.  Structure and expression of the human apolipoprotein A-IV gene. , 1987, The Journal of biological chemistry.

[33]  M. Lefevre,et al.  The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from an ether analog of phosphatidylcholine. , 1986, Biochimica et biophysica acta.

[34]  G. Dallinga-Thie,et al.  Tissue Sites of Degradation of High Density Lipoprotein Apolipoprotein A‐IV in Rats , 1986, Arteriosclerosis.

[35]  J. Albers,et al.  Activation of lecithin: cholesterol acyltransferase by apolipoproteins E-2, E-3, and A-IV isolated from human plasma. , 1985, Biochimica et biophysica acta.

[36]  P. Groot,et al.  Distribution of apolipoprotein A-IV among lipoprotein subclasses in rat serum. , 1985, Journal of lipid research.

[37]  G. Utermann,et al.  Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV. , 1985, The Journal of biological chemistry.

[38]  C. Bisgaier,et al.  Distribution of apolipoprotein A-IV in human plasma. , 1985, Journal of lipid research.

[39]  K. Saku,et al.  Renal handling of high-density lipoproteins by isolated perfused kidneys. , 1984, Metabolism: clinical and experimental.

[40]  D. Steinberg,et al.  Tissue sites of degradation of apoprotein A-I in the rat. , 1983, The Journal of biological chemistry.

[41]  C. Tisher,et al.  Uptake and intracellular distribution of ferritin in the rat distal convoluted tubule. , 1982, Kidney international.

[42]  E. Quinet,et al.  Human apolipoprotein A-IV. Intestinal origin and distribution in plasma. , 1980, The Journal of clinical investigation.

[43]  E. Quinet,et al.  INTESTINAL ORIGIN AND DISTRIBUTION IN PLASMA , 1980 .

[44]  G. Utermann,et al.  Apolipoprotein A-IV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma. Isolation and quantification. , 1979, European journal of biochemistry.

[45]  B. Brenner,et al.  Permselectivity of the glomerular capillary wall. Facilitated filtration of circulating polycations. , 1978, The Journal of clinical investigation.

[46]  H. Eder,et al.  Polypeptide composition of rat high density lipoprotein: characterization by SDS-gel electrophoresis. , 1974, Biochemical and Biophysical Research Communications - BBRC.